Abstract: An anti-inflammatory drug compound, and a preparation method therefor and the use thereof. The structural formula of the compound is A-Y—B, wherein A is a group after dehydrogenation of an amine compound having JAK inhibitory activity, Y is a direct connection or —(CH2)-O— or, and B is a group formed by means of dehydroxylation of a carboxy-containing carboxylic acid compound B1, or a group formed by means of dehydrogenation of a hydroxy-containing compound B2. The compound has the special effects of having a strong transdermal property, controlled drug release, high efficacy, etc.

Abstract: Disclosed herein are drug delivery systems and methods for locally delivering therapeutic agents, and methods for using such drug delivery systems for the treatment of diseases.

Abstract: An external anti-inflammatory drug compound, and a preparation method therefor and the use thereof. The structural formula of the compound is A-Y—B, wherein A is a group after dehydrogenation of an amine compound having JAK inhibitory activity, Y is a direct connection or —(CH2)—O— or, and B is a group formed by means of dehydroxylation of a carboxy-containing carboxylic acid compound B1, or a group formed by means of dehydrogenation of a hydroxy-containing compound B2. The compound has the special effects of having a strong transdermal property, controlled drug release, high efficacy, etc.

Abstract: Provided are prodrugs for sustained releasing therapeutic agents, and methods for using such prodrugs for the treatment of diseases.

Abstract: Provided herein are drug delivery systems and methods for locally delivering therapeutic agents, and methods for using such drug delivery systems for the treatment of diseases.

Abstract: A metering device and metering method for metering carbon dioxide flow belong to the technical field of preparation of polyurethane foam materials. The metering device of the present invention has a simple structure and a small size, can accurately control the amount of the delivered liquefied carbon dioxide; meanwhile, one end of the metering pump is connected with the sliding block, and the sliding block can move on the transverse plate, thus changing the vertical movement stroke of the piston rod and changing the flow volume of the carbon dioxide. The cylinder of the metering pump of the present invention is internally provided with the water passages, and a coolant can be filled into the water passages to keep the temperature of the carbon dioxide constant.

Abstract: A metering device and metering method for metering carbon dioxide flow belong to the technical field of preparation of polyurethane foam materials. The metering device of the present invention has a simple structure and a small size, can accurately control the amount of the delivered liquefied carbon dioxide; meanwhile, one end of the metering pump is connected with the sliding block, and the sliding block can move on the transverse plate, thus changing the vertical movement stroke of the piston rod and changing the flow volume of the carbon dioxide. The cylinder of the metering pump of the present invention is internally provided with the water passages, and a coolant can be filled into the water passages to keep the temperature of the carbon dioxide constant.

Abstract: The present invention relates to a compound of formula I: wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; and methods of using such compounds to, for example, treat a bacterial infection.

Abstract: The invention relates to a crystalline form of a triethylamine salt of (2Z)-2-(2 -amino-5-chlorothiazol-4-yl)-2-(3-N-tert-butoxycarbonylaminopropoxyimino)acetic acid. The invention also relates to processes and intermediates for preparing the crystalline form. The crystalline form is useful as an intermediate for preparing cross-linked glycopeptide-cephalosporin antibiotics.

Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.

Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.

Abstract: The invention provides crystalline solid forms of (((S)-1-{(S)-2-[4-(4?-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2?-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat hepatitis C virus infection, and processes useful for preparing such crystalline solid forms.

Abstract: The invention relates to a crystalline form of a triethylamine salt of (2Z)-2-(2-amino-5-chlorothiazol-4-yl)-2-(3-N-tert-butoxycarbonylaminopropoxyimino)acetic acid. The invention also relates to processes and intermediates for preparing the crystalline form. The crystalline form is useful as an intermediate for preparing cross-linked glycopeptide-cephalosporin antibiotics.

Abstract: The present invention relates to a compound of formula I: wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; and methods of using such compounds to, for example, treat a bacterial infection.

Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.

Abstract: The invention provides crystalline solid forms of (((S)-1-{(S)-2-[4-(4?-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2?-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat hepatitis C virus infection, and processes useful for preparing such crystalline solid forms.